DALLAS, Feb. 24, 2010 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring XenoPort Inc. (Nasdaq:XNPT). The report includes financial, comparative and investment analysis, and industry information you need to know to make an educated investment decision.
The full report is available at: http://www.stockpreacher.com/n/XNPT
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/StockPreacher
XenoPort Inc. (XNPT) is a biopharmaceutical company. The Company is focused on developing a portfolio of internally discovered product candidates that utilize the body's natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs. The Company focuses on development and commercialization efforts on potential treatments of central nervous system (CNS) disorders. Its product candidate, XP13512, known in the United States by the trade name Solzira (gabapentin enacarbil) Extended Release Tablets, is being developed for the treatment of a number of CNS disorders. During the year ended December 31, 2008, XP13512 completed a Phase IIa clinical trial for the management of post-herpetic neuralgia (PHN), in the United States.
Message Board Search for XNPT: http://www.boardcentral.com/boards/XNPT
In the report, the analyst notes:
"Revenues for the quarter were $5.8 million, compared to $10.6 million for the same period in 2008. Net loss for the fourth quarter was $18.3 million, compared to a net loss of $18.7 million for the same period in 2008. At December 31, 2009, XNPT had cash and cash equivalents and short-term investments of $143.7 million.
"GlaxoSmithKline (NYSE:GSK) and XNPT last week received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Horizant(TM)(gabapentin enacarbil) Extended-Release Tablets, an investigational non-dopaminergic treatment for moderate-to-severe primary Restless Legs Syndrome (RLS). A Complete Response letter is issued by the FDA's Center of Drug Evaluation and Research when the review of a file is completed and questions remain that preclude the approval of the NDA in its current form."
To read the entire report visit: http://www.stockpreacher.com/n/XNPT
See what investors are saying about XNPT at penny stock forum
StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com
StockPreacher.com Disclosure
StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly owned by BlueWave Advisors, LLC. StockPreacher.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.